Various markers of bone metabolism are used to help develop treatment plans for osteoporosis or for assessing therapeutic effects of osteoporosis medications. Many investigations have examined the effects of various bone metabolism markers 1-3 , but few have examined correlations across multiple types of bone metabolism markers. We investigated correlations
Takashi NAGAI, et al 166 between various bone metabolism markers to determine which could be used as a universal marker of bone metabolism and its associated care.
Subjects and Methods
Subjects comprised female patients treated for osteoporosis at this facility between January and December 2009 in whom the following bone metabolism markers were measured on the same day : bone alkaline phosphatase BAP ; cross-linked N-telopeptide of type I collagen urine NTX ; osteocalcin OC ; undercarboxylated osteocalcin ucOC ; and tartrateresistant acid phosphatase TRACP-5b . There were 144 subjects, with a mean age of 71.2 years range : 34-92 years . The pathology underlying the need for treatment was primary osteoporosis in 141 subjects, and secondary osteoporosis in 3 subjects steroid induced in 2 subjects ; ovarian failure in 1 subject .
BAP, urine NTX, OC, ucOC, and TRACP-5b levels were measured at the initial visit or during a periodic checkup. In addition, samples were taken for hematology. Blood and urine biochemistry, and urine Ca/Cr levels were also investigated. Urine NTX and urine Ca/Cr were measured from the second morning urine.
All 144 subjects were analyzed as a total group. The subjects were also divided into 2 groups and analyzed based on whether they were using an osteoporosis drug or not. Subjects currently using osteoporosis medications were included in the treated group n=113 ; mean age : 71.9 years , and subjects with no treatment experience were included in the untreated group n=31 ; mean age : 68.6 years . Drugs used by subjects in the treated group were as follows : 14 patients took etidronate drug alone : n=8 ; concomitant vitamin D : n=3 ; concomitant calcium : n=3 ; 34 patients took alendronate drug alone : n=20 ; concomitant vitamin D : n=12 ; concomitant calcium : n=2 ; 27 patients took risedronate drug alone : n=17 ; concomitant vitamin D : n=5 ; concomitant calcium : n=2 ; concomitant vitamin K : n=1 ; concomitant vitamin D and calcium : n=1 ; concomitant vitamin D and vitamin K : n=1 ; 10 patients took raloxifene drug alone : n=8 ; concomitant vitamin D : n=1 ; concomitant calcium : n=1 ; 3 patients took vitamin K ; 16 patients took vitamin D ; 6 patients took vitamin D and calcium ; 1 patient took calcium ; 1 patient took vitamin K and calcium ; and one patient took conjugated estrogens. 2 subjects were taking warfarin in the present study.
Data were statistically analyzed using Pearson s correlation coef cient with a two-tailed signi cance level of P 0.05. Statistical analysis was performed using Stat Mate III version 3.14 ATMS, Tokyo, Japan .
The study protocol was reviewed and approved by the Medical Ethics Review Board of Showa University School of Medicine approval number : 1053 .
Results
In the total group, significant differences between parameters were observed for BAP, urine NTX, OC, ucOC, and TRACP-5b P 0.05 to P 0.001 ; Fig. 1a between BAP, urine NTX, OC, ucOC, and TRACP-5b were observed Table 2 . No correlations with urine Ca/Cr were apparent. In the untreated group, no signi cant correlation was observed between BAP and ucOC, but correlations between BAP, urine NTX, OC, ucOC, and TRACP-5b were observed Table 3 . No correlation was seen between urine Ca/Cr and any other parameter.
Discussion
Clinical measurement of bone metabolism markers enables the condition of bony tissue/ bone metabolism to be assessed 1 , allows prediction of fracture risk 4, 5 and risk of bone loss in the near future 2 , and enables drug therapies for osteoporosis to be practically assessed.
In addition, conveying these results to patients can help increase patient compliance in taking osteoporosis medications. Results can also be used to screen for bone metastases from tumorous lesions 6 . Changes in bone metabolism markers can occur due to age, sex, a b c Fig. 1 . Correlation between bone metabolism markers in the total group. Significant correlations were observed between BAP, urine NTX, TRACP-5b, OC, and ucOC. 3 , diabetes mellitus, and thyroid dysfunction 7, 8 . In general, bone metabolism becomes more active at night than during the day, and after decreasing in the afternoon, almost all markers of bone metabolism are present at high levels at night then decrease in the morning 9, 10 . As a result, samples must be taken within the same time frame. In the present study, most of the patients had primary osteoporosis, and their results could not be compared to the results from the 3 patients with secondary osteoporosis because of the small number. By increasing the number of subjects, we hope to conduct further analyses on correlations between bone metabolism markers and the causes of osteoporosis, such as in patients with steroid-induced secondary osteoporosis.
Various types of bone metabolism markers are known, but the present study only variations in values appear to re ect drug ef cacy more acutely than small variations. We believe that U-NTX is a more useful marker for the evaluation of bone resorption ; on the other hand, BAP is more useful as an osteoplastic marker. In addition, although two types of bone metabolism markers are available bone resorption markers and osteoplastic markers , the therapeutic effect of osteoporosis drugs is better assessed in clinical practice when the same type of bone metabolism marker is tested, rather than changing the type of marker with each test. In the present study, urine Ca/Cr levels showed no correlation with any other marker of bone metabolism in either the total group, untreated group, or treated group. However, we reported previously that signi cant differences in urine Ca/Cr levels are effective for assessing therapeutic effects 12 . In view of the results from the present study, although problems remain with the use of urine Ca/Cr levels as a single indicator of bone metabolism, it is still a necessary parameter for the early detection of hypercalciuria.
In the total group and the treated group, ucOC correlated with urine NTX, BAP, OC, and TRACP-5b. However, there was no correlation between ucOC and BAP in the untreated group. Although ucOC is a marker of bone metabolism, it is also useful as an indicator of the state of vitamin K intake 13 . Vitamin K has an effect on the blood coagulation system, but an antagonistic action occurs when vitamin K is administered to patients taking the anticoagulant warfarin. As a result, caution is necessary when administering vitamin K to patients on warfarin. Vitamin K also functions as a coenzyme of -glutamyl carboxylase. Gamma-glutamyl carboxylase catalyzes the carboxylation of glutamate Glu residues in vitamin-K-dependent proteins to produce -carboxyglutamate Gla residues. A negative correlation exists between the formation of Gla and osteoporotic fractures 14, 15 .
Low Gla-osteocalcin blood levels were reportedly more common in a group of patients with fractures than in a control group, and the incidence of new femoral neck fracture was higher in the group with a higher incidence of low Gla-osteocalcin blood levels 14 . Only 2 subjects were taking warfarin in the present study. The ucOC level was slightly higher in case 1 and remarkably higher in case 2 than the average level Table 4 . We think ucOC level was higher in the warfarin treated group because the intake of vitamin K was restricted in that group.
The ultimate objective of osteoporosis treatment is fracture prevention. Although markers of bone metabolism are useful for their evaluative and predictive properties, conducting simultaneous tests with many markers is not economical. ucOC is a marker of bone metabolism, and also indicates the state of vitamin K intake. Based on the results from this study, the correlations between both bone resorption markers and osteoplastic markers identi ed ucOC as the best universal bone metabolism marker to use in the clinical setting.
